JLK’s AI medical solution for LVO nears U.S. FDA approval

JLK Co. CI

JLK Co., the first publicly listed company in South Korea specializing in medical artificial intelligence, announced on Wednesday that its AI solution for detecting large vessel occlusion (LVO), JLK-LVO, has been published in the international journal “Frontiers in Neurology.”

“We have demonstrated the clinical value of our AI solution for detecting large vessel occlusion by publishing a performance validation paper in the renowned journal ‘Frontiers in Neurology,’” the company said.

The research team validated the performance of JLK-LVO using computed tomography (CT) angiography data from 2,045 domestic stroke patients

The results showed that JLK-LVO achieved about 95 percent sensitivity and specificity in diagnosing intracranial internal carotid artery (ICA) and M1 middle cerebral artery (M1-MCA) occlusions that require vascular recanalization procedures.